[{"Assets_0_Q3_USD":1267800000.0,"CommonStockSharesOutstanding_0_Q3_shares":68100000.0,"EarningsPerShareBasic_1_Q3_USD":0.06,"EarningsPerShareBasic_3_Q3_USD":0.13,"EarningsPerShareDiluted_1_Q3_USD":0.06,"EarningsPerShareDiluted_3_Q3_USD":0.13,"NetIncomeLoss_1_Q3_USD":4200000.0,"NetIncomeLoss_3_Q3_USD":9000000.0,"StockholdersEquity_0_Q3_USD":748200000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":68300000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":68500000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":68100000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":68100000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-Q","period":"20170331","fy":"2017.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20170503"}]